ArticleJournal of cosmetic dermatology2025
Skin Improvement in Japanese Patients With Inflammatory Dermatologic Conditions Using the Injectable Hyaluronic Acid VYC-12.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundMany skin disorders of the face have an inflammatory element, including atopic dermatitis, acne vulgaris, and rosacea. VYC-12 is an injectable hyaluronic acid product with well-established hydrating effects and potential anti-inflammatory benefits.
aimsTo assess the utility of VYC-12 for improving inflammatory skin conditions.
methodsThis was a single-center, retrospective analysis of adults with a facial inflammatory skin condition that was resistant to standard treatments. A small group was also included who only required treatment for aging-related concerns. VYC-12 was injected into the deep dermis based on the standard technique. Imaging was used to assess skin redness and stratum corneum moisture levels. Patient satisfaction was evaluated on a five-point Likert scale, and adverse events were recorded throughout a mean follow-up of 4 months.
resultsFifteen patients were included (86.7% female; mean age: 40.5 ± 9.7 years). Four had atopic dermatitis, 4 had acne vulgaris, and 2 had rosacea; the other 5 had aging-related dryness and fine lines. Patients received a mean of 3.4 ± 1.2 mL of VYC-12. Among 10 individuals with an inflammatory skin condition, mean skin redness decreased from 57.7 (arbitrary units) at baseline to 47.9 at 4 months post-treatment (p < 0.0005); mean stratum corneum moisture levels increased from 45.1 (arbitrary units) to 75.3 over this period (p < 0.0005). All 15 subjects were satisfied with the results. There were no adverse events.
conclusionsVYC-12 significantly improved skin redness and hydration in patients with inflammatory skin disorders. Further studies are warranted to assess the benefits of combining VYC-12 with standard treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.